RNASE4

Across TCGA pan-cancer cohorts, RNASE4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RNASE4 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RNASE4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RNASE4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

CESC, SKCM, and LIHC are the cancer types where RNASE4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.192	0.798	<.001	30	view →
SKCM	OS	Median	All	0.230	0.781	.004	15	view →
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.445	.048	2	view →
HNSC	DFS	Median	All	1.000	0.308	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RNASE4–CESC (OS)

Open the CESC breakdown →